Month: January 2017

NCPA Advocacy Center Update – Week Ending January 28, 2017

NCPA Supports House Bill Recognizing Pharmacists as Health Care Providers:  This week NCPA endorsed H.R. 592, the Pharmacy and Medically Underserved Areas Enhancement Act, which was introduced by U.S. Reps. Brett Guthrie (R-Ky.), G.K. Butterfield (D-N.C.), Tom Reed (R-N.Y.) and

NCPA Advocacy Center Update – Week Ending January 21, 2017

NCPA Members List Top 2017 Political Priorities:   For the fourth consecutive year, NCPA has asked its members to rank their most important legislative and regulatory priorities. The top issue chosen by respondents is to end the retroactive nature of DIR

NCPA Advocacy Center Update – SPECIAL ALERT – January 19, 2017

Hi all –NCPA is pleased to report that CMS released an analysis related to Part D DIR fees and the impact of these fees on the Part D program today.  The CMS analysis is an important step toward greater transparency

NCPA Advocacy Center Update – Week Ending January 14, 2017

NCPA Asks President-elect Trump to Scrutinize Pharmacy Benefit Managers in Review of Prescription Drug Prices:  This week NCPA sent a letter to President-elect Donald J. Trump urging his Administration to examine the role pharmacy benefit managers (PBMs) play in escalating

NCPA Advocacy Center Update – Week Ending December 24, 2016

DEA Revises Registrant Renewal Policy:  Heeding the concerns of NCPA and other registrants, the DEA has quickly revised a recently-issued policy change on renewal applications that could have decreased patient access to controlled substances and had audit implications for pharmacies. Starting